Studies show Ofev reduces acute exacerbations of IPF, slows disease progression
Analysis of the pooled data shows that Ofev slows disease progression by 50 percent and reduces acute exacerbations by more than 47 percent. The analysis is based on data compiled from phase-two Tomorrow trials and two phase-three Inpulsis trials. More than 1,200 individuals with IPF took part in the trials, with approximately 700 of them treated with Ofev, the rest with a placebo. Results were published in Respiratory Medicine.
IPF is a debilitating, life-threatening lung disease. Acute exacerbations -- the sudden worsening of respiratory conditions without known causes -- often lead to hospitalization for those with the disease. Approximately half of all hospitalized for the exacerbation die during the hospital stay. The findings also demonstrate that Ofev reduces the risk of death from the disease by at least 30 percent.
“Reducing the risk of exacerbations is an important treatment goal in the management of IPF because of their unpredictability and devastating impact on the course of the disease,” Luca Richeldi, professor of respiratory medicine at the University of Southampton, said. “Acute exacerbations often lead to death within a few months. Analyses like these add to the growing body of evidence that we may see people with IPF live longer because recently approved treatments have an impact on the course of the disease.”
Organizations in this story
Boehringer-Ingelheim 900 Ridgebury Rd Ridgefield, CT 06877